Search Our Site

News tagged with:

"cancer"

Pap Test Fluids Used In Gene-Based Screening Test for Two Gyn Cancers

Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers developed by researchers at the Johns Hopkins Kimmel Cancer Center. PapSEEK detects mutations in DNA that have been identified for specific cancers sooner. Earlier detection of cancer could lead to earlier treatment and... Read More »

Read More →

Cervical fluid samples gathered during routine Papanicolaou (Pap) tests are the basis of a new screening test for endometrial and ovarian cancers developed by researchers at the Johns Hopkins Kimmel Cancer Center. PapSEEK detects mutations in DNA that have been identified for specific cancers sooner. Earlier detection of cancer could lead to earlier treatment and… Read More »

[...]

Read More

Newer Breast MRI May Be More Accurate and Easier

A new type of MRI (magnetic resonance imaging) that doesn’t use a contrast agent appears better at detecting what’s really cancer and what’s likely just a harmless lesion, researchers report. In a study in Germany, the new technique reduced false-positive findings by 70 percent. The scan was also able to detect 98 percent of breast... Read More »

Read More →

A new type of MRI (magnetic resonance imaging) that doesn’t use a contrast agent appears better at detecting what’s really cancer and what’s likely just a harmless lesion, researchers report. In a study in Germany, the new technique reduced false-positive findings by 70 percent. The scan was also able to detect 98 percent of breast… Read More »

[...]

Read More

Screening, Treatment Cuts Breast Cancer Deaths in Half

Breakthroughs in breast cancer screening and treatment have slashed the percentage of women dying from the disease, a new analysis reveals. “Advances in screening and treatment are saving lives,” said lead researcher Sylvia Plevritis, a professor of radiology and biomedical data science at the Stanford University School of Medicine. “Here’s an example that all this... Read More »

Read More →

Breakthroughs in breast cancer screening and treatment have slashed the percentage of women dying from the disease, a new analysis reveals. “Advances in screening and treatment are saving lives,” said lead researcher Sylvia Plevritis, a professor of radiology and biomedical data science at the Stanford University School of Medicine. “Here’s an example that all this… Read More »

[...]

Read More

Pfizer Breast Cancer Drug Superior to Chemotherapy in Late Stage Study

(Reuters) – Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer Inc drug went about three months longer before their disease worsened than those who received chemotherapy in a late stage study, according to data released on Friday. The drug, talazoparib, a once daily pill that... Read More »

Read More →

(Reuters) – Patients with advanced breast cancer tied to an inherited gene mutation who were treated with an experimental Pfizer Inc drug went about three months longer before their disease worsened than those who received chemotherapy in a late stage study, according to data released on Friday. The drug, talazoparib, a once daily pill that… Read More »

[...]

Read More

FDA approves first biosimilar for the treatment of certain breast and stomach cancers

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or... Read More »

Read More →

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or… Read More »

[...]

Read More

FDA approves first-of-a-kind test for cancer gene profiling

U.S. regulators have approved a first-of-a-kind test that looks for mutations in hundreds of cancer genes at once, giving a more complete picture of what’s driving a patient’s tumor and aiding efforts to match treatments to those flaws. The U.S. Food and Drug Administration approved Foundation Medicine’s test for patients with advanced or widely spread... Read More »

Read More →

U.S. regulators have approved a first-of-a-kind test that looks for mutations in hundreds of cancer genes at once, giving a more complete picture of what’s driving a patient’s tumor and aiding efforts to match treatments to those flaws. The U.S. Food and Drug Administration approved Foundation Medicine’s test for patients with advanced or widely spread… Read More »

[...]

Read More

Gene Therapy May Fight Brain Cancer’s Return

A new form of gene therapy shows promise in battling recurrent brain cancer. The phase 1 clinical trial included 56 patients with recurrent high-grade glioma brain cancer. Three years after the gene therapy treatment, more than a quarter of the patients were still alive. Median survival for patients was 14.4 months, compared with eight months... Read More »

Read More →

A new form of gene therapy shows promise in battling recurrent brain cancer. The phase 1 clinical trial included 56 patients with recurrent high-grade glioma brain cancer. Three years after the gene therapy treatment, more than a quarter of the patients were still alive. Median survival for patients was 14.4 months, compared with eight months… Read More »

[...]

Read More

7 Medical Conditions That Will Be Lining Big Pharma’s Pockets by 2020

Imagine a stack of dollar bills reaching from the ground to more than 95,000 miles into the sky — nearly four-tenths of the way to the moon. That stack would total $1.4 trillion. It’s a staggering number. It’s also how much will be spent worldwide on medications by 2020, according to a report from QuintilesIMS. That’s... Read More »

Read More →

Imagine a stack of dollar bills reaching from the ground to more than 95,000 miles into the sky — nearly four-tenths of the way to the moon. That stack would total $1.4 trillion. It’s a staggering number. It’s also how much will be spent worldwide on medications by 2020, according to a report from QuintilesIMS. That’s… Read More »

[...]

Read More

Read the Fine Print on the $475,000 Price of a Cancer Breakthrough

Novartis could have priced Kymriah much higher, and it’s being unusually flexible. Kicking it off, Gilead Sciences Inc. bought Kite Pharma Inc., a pioneer in “CAR-T” cell therapy, which uses a patient’s immune cells to potentially eradicate blood cancers with just one treatment. And on Wednesday, Novartis AG’s entry in this field, Kymriah, became the first such... Read More »

Read More →

Novartis could have priced Kymriah much higher, and it’s being unusually flexible. Kicking it off, Gilead Sciences Inc. bought Kite Pharma Inc., a pioneer in “CAR-T” cell therapy, which uses a patient’s immune cells to potentially eradicate blood cancers with just one treatment. And on Wednesday, Novartis AG’s entry in this field, Kymriah, became the first such… Read More »

[...]

Read More

‘Pen’ identifies cancer in 10 seconds

They say it could make surgery to remove a tumour quicker, safer and more precise. And they hope it would avoid the “heartbreak” of leaving any of the cancer behind. Tests, published in Science Translational Medicine, suggest the technology is accurate 96% of the time. The MasSpec Pen takes advantage of the unique metabolism of... Read More »

Read More →

They say it could make surgery to remove a tumour quicker, safer and more precise. And they hope it would avoid the “heartbreak” of leaving any of the cancer behind. Tests, published in Science Translational Medicine, suggest the technology is accurate 96% of the time. The MasSpec Pen takes advantage of the unique metabolism of… Read More »

[...]

Read More

Page 1 of 4

Categories
Archives